[1]
Department of Health and Ageing. Therapeutic Goods and Administration: Australian Public Assessment Report for Pralatrexate 2013.
[2]
Liu, C.; Yang, C.; Lu, L.; Wang, W.; Tan, W.; Leung, C.H.; Ma, D.L. Luminescent iridium(III) complexes as COX-2-specific imaging agents in cancer cells. Chem. Commun. , 2017, 53, 2822-2825.
[3]
Lin, S.; Lu, L.; Kang, T.; Mergny, J.L.; Leung, C.H.; Ma, D.L. Interaction of an Iridium (III) Complex with G-Quadruplex DNA and its application in luminescent switch- on detection of Siglec-5. Anal. Chem., 2016, 88, 10290-10295.
[4]
Wang, W.; Vellaisamy, K.; Li, G.; Wu, C.; Ko, C.N.; Leung, C.H.; Ma, D.L. Development of a long-lived luminescence probe for visualizing β-Galactosidase in ovarian carcinoma cells. Anal. Chem., 2017, 89, 11679-11684.
[5]
Hori, Y.; Otomura, N.; Nishida, A.; Nishiura, M.; Umeno, M.; Suetake, I.; Kikuchi, K. Synthetic-molecule/protein hybrid probe with fluorogenic switch for live - cell imaging of dna methylation. J. Am. Chem. Soc., 2018, 140, 1686-1690.
[6]
Nicholas, W.; Davis, III P.J.; Yu, Z.; Chan, J. NitroxyFluor: A thiol-based fluorescent probe for live-cell imaging of nitroxyl. J. Am. Chem. Soc., 2017, 139, 18476-18479.
[7]
Wu, C.; Vellaisamy, K.; Yang, G.; Dong, Z.Z.; Leung, C.H.; Liu, J.B.; Ma, D-K. A reaction-based luminescent switch-on sensor for the detection of OH- ions in simulated waste water. Dalton Trans., 2017, 46, 6677-6682.
[8]
Yadav, N.; Singh, P.; Mehrotra, R. Evaluation of stability of 5- fluorouracil under different stress conditions: high performance liquid chromatography and infrared spectroscopic approach. Curr. Pharm. Anal., 2012, 8, 49-55.
[9]
Hanif, M.; Akhtar, M.F.; Naeem, S.; Wahid, M.; Shehzad, M.A.; Saadullah, M.; Nasir, B.; Afzal, S. Development and validation of a new hplc method for the detection of 5-fluorouracil in mobile phase and in plasma. Curr. Pharm. Anal., 2018, 14, 3-7.
[10]
He, W.; Jennifer, H.; Martin, P.N.; Lu, S.W.; Euan, T.; Walpole, G.D. A simple and sensitive LC-MS/MS method for the simultaneous determination of cyclophosphamide and doxorubicin concentrations in human plasma. Curr. Pharm. Anal., 2018, 14, 53-59.
[11]
ICH Q 6A(R2), Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances (step4), in: International Conference on Harmonization, Geneva,, 2006.
[12]
ICH Q3B(R2), Impurities in new drug products (step4), in: International Conference on Harmonization, Geneva,, 2006.
[13]
Kulsum, S.; Sagar, G.V. Validated RP-HPLC method for the determination of pralatrexate in bulk and pharmaceutical dosage forms. World J. Pharm. Pharm. Sci., 2015, 5, 1173-1171.
[14]
Sastry, R.V.R.P.; Venkatesan, C.S.; Sastry, B.S.; Mahesh, K. Identification and characterization of forced degradation products of pralatrexate injection by LC-PDA and LC-MS. J. Pharm. Biomed. Anal., 2016, 131, 400-409.
[15]
Chatterji, D.; Gallelli, J.F. Thermal and photolytic decomposition of methotrexate in aqueous solutions. J. Pharm. Sci., 1978, 67, 526-531.
[16]
Gupta, A.; Ahmad, W.; Iqbal, J.; Zaheer, M.R. Photochemical electron transfer reactions of talotrexin. Int. J. Phar. Res., 2016, 7, 190-195.
[17]
Sato, N.; Saito, N. Studies on pyrazines. 17. [1]. An efficient synthesis of pteridine-6-carboxylic acids. J. Heterocycl. Chem., 1988, 25, 1737.
[18]
Dion, R.L.; Loo, T.L. The oxidation of certain pteroylglutamic acid analogs. J. Org. Chem., 1961, 26(6), 1857-1859.
[19]
DailyMed-FOLOTYN- pralatrexate injection, Allos Therapeutics. 2016.
[20]
ICH Q1A (R2), Stability testing of new drug substances and products (STEP4), in: International Conference on Harmonization, Geneva,, 1996.
[21]
ICH Q1B, Stability testing: photo stability testing of new drug substances and products (step4), in: International Conference on Harmonization, Geneva,, 1996.
[22]
ICH Q2 (R1) Validation of analytical procedures: Text and Methodology (STEP4), in: International Conference on Harmonization, Geneva1996.
[23]
Center for Drug Evaluation and Research (CDER), Reviewer Guidance, Validation of Chromatographic Methods 1994.
